MedTrace Logo

TACE With or Without SBRT as Bridging Therapy for Pre-transplant HCC Patients

NCT01918683 · Status: ACTIVE_NOT_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2026-01-29

No results posted yet for this study

Summary

This trial is designed to be the initial prospective pilot investigation of the effectiveness of combined SBRT and TACE as bridging therapy for HCC patients awaiting liver transplanation. No prospective clinical trials regarding the combination of TACE and SBRT in pre-transplant population have been performed. We propose the trial be conducted as a pilot clinical trial with the goal of enrolling 40 patients into each arm

Conditions

Interventions

RADIATION

TACE transarterial chemoembolization

RADIATION

stereotatic body radiotherapy (SBRT)

Sponsors & Collaborators

  • Loyola University

    collaborator OTHER

  • Oregon Health and Science University

    collaborator OTHER

  • Abramson Cancer Center at Penn Medicine

    lead OTHER

Principal Investigators

  • Edgar Ben-Josef, MD · Abramson Cancer Center at Penn Medicine

  • Tarita Thomas, MD, PhD · Loyola University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-07-31
Primary Completion
2026-12-31
Completion
2027-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01918683 on ClinicalTrials.gov